Author Affiliations: Department of Hematology (Dr R. Li and Mss Shen and Yang), Department of Nursing (Ms Yao), and the Union (Ms Chan), Children's Hospital Affiliated to Soochow University; and School of Nursing (Ms Zhang, and Dr H. Li), Soochow University.
Cancer Nurs. 2024;47(5):E348-E359. doi: 10.1097/NCC.0000000000001261. Epub 2023 Jul 31.
Children with acute lymphoblastic leukemia (ALL) experience multiple symptoms during chemotherapy. Assessing how symptoms cluster together and how these symptom clusters (SCs) change over time may lay a foundation for future research in SC management and the pathophysiological mechanisms of SCs.
This study aimed to assess the stability of SCs in children with ALL during chemotherapy.
A longitudinal investigation was carried out. The Chinese version of the Memorial Symptom Assessment Scale 10 to 18 was used to assess the occurrence, severity, and distress of symptoms in 134 children with ALL (8-16 years old) at the following 4 separate points: before chemotherapy (T1), start of post-induction therapy (T2), 4 months post-induction therapy (T3), and start of maintenance therapy (T4). Exploratory factor analyses were used to extract SCs.
Six SCs were identified. Emotional and somatic clusters were identified across all dimensions and time points. Gastrointestinal cluster was all identified except for occurrence at T1. Neurological cluster was identified at T2 and T3 for all dimensions and at T4 for severity and distress. Self-image disorder cluster was all identified except at T1. Skin mucosa cluster was identified at T2 and T3 for all dimensions. Emotional cluster exhibited common symptoms across dimensions and time points.
The number and types of SCs determined by scoring the occurrence, severity, and distress are different, but some SCs are relatively stable.
Clinicians should not only focus on the common trajectory of symptoms and SCs, but also assess each child individually.
儿童急性淋巴细胞白血病(ALL)在化疗期间会出现多种症状。评估症状如何聚类以及这些症状聚类(SCs)随时间的变化可能为未来的 SC 管理和 SCs 的病理生理机制研究奠定基础。
本研究旨在评估化疗期间 ALL 患儿 SCs 的稳定性。
进行了一项纵向研究。使用中文版 Memorial 症状评估量表 10-18 评估 134 名 8-16 岁 ALL 患儿在以下 4 个不同时间点(化疗前(T1)、诱导治疗开始时(T2)、诱导治疗后 4 个月(T3)和维持治疗开始时(T4))的症状发生、严重程度和痛苦。采用探索性因子分析提取 SCs。
确定了 6 个 SCs。情绪和躯体聚类在所有维度和时间点均被识别。除 T1 时的发生外,胃肠道聚类也被识别。神经聚类在 T2 和 T3 时所有维度和 T4 时严重程度和痛苦时被识别。自我形象障碍聚类除 T1 外均被识别。皮肤黏膜聚类在 T2 和 T3 时所有维度均被识别。情绪聚类在各个维度和时间点都有共同的症状。
通过评分发生、严重程度和痛苦来确定的 SCs 的数量和类型不同,但有些 SCs 相对稳定。
临床医生不仅要关注症状和 SCs 的共同轨迹,还要对每个孩子进行单独评估。